Cover Image
Read Now

Clinical review report: Bictegravir/Emtricitabine/Tenofovir alafenamide (B/FTC/TAF) (Biktarvy) (Gilead Sciences Canada, Inc.) indication : a complete regimen for the treatment of HIV-1 infection in adults with no known substitution associated with resistance to the individual components of Biktarvy

The objective of this systematic review was to evaluate the efficacy and safety of the fixed-dose combination (FDC) bictegravir/emtricitabine/tenofovir alafenamide (B/FTC/TAF) 50 mg/200 mg/25 mg, once daily, as a treatment for HIV type 1 (HIV-1) infection in adults with no known substitution associa...

Full description

Bibliographic Details
Corporate Author: Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 2018, October 2018
Series:CADTH common drug review
Subjects:
Antiretroviral Therapy, Highly Active
Canada
Tenofovir / Therapeutic Use
Emtricitabine / Therapeutic Use
Hiv Infections / Drug Therapy
Treatment Outcome
Anti-hiv Agents / Therapeutic Use
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Description
Summary:The objective of this systematic review was to evaluate the efficacy and safety of the fixed-dose combination (FDC) bictegravir/emtricitabine/tenofovir alafenamide (B/FTC/TAF) 50 mg/200 mg/25 mg, once daily, as a treatment for HIV type 1 (HIV-1) infection in adults with no known substitution associated with resistance to the individual components of B/FTC/TAF. Of which, B is an integrase strand transfer inhibitor, and both emtricitabine (FTC) and tenofovir alafenamide (TAF) are nucleoside reverse transcriptase inhibitors
Item Description:"Version: Final with redactions."
Physical Description:1 PDF file (90 pages)

Similar Items